Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)
by Michael Walen · The Markets DailyNexentis Technologies (NASDAQ:NXTS – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Profitability
This table compares Nexentis Technologies and Palisade Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
| Palisade Bio | N/A | -33.47% | -31.79% |
Valuation & Earnings
This table compares Nexentis Technologies and Palisade Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexentis Technologies | $210,000.00 | 3.62 | -$4.00 million | ($96.07) | -0.01 |
| Palisade Bio | $250,000.00 | 927.12 | -$16.78 million | ($0.48) | -2.77 |
Nexentis Technologies has higher earnings, but lower revenue than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Nexentis Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for Nexentis Technologies and Palisade Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Palisade Bio | 1 | 0 | 8 | 2 | 3.00 |
Palisade Bio has a consensus price target of $9.29, indicating a potential upside of 598.17%. Given Palisade Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Nexentis Technologies.
Risk and Volatility
Nexentis Technologies has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
Institutional and Insider Ownership
61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Palisade Bio beats Nexentis Technologies on 9 of the 14 factors compared between the two stocks.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.